Salute e Benessere

Microban International Appoints Shermon McMillan as New President

As president, McMillan will focus on building the Microban brand and growing the company's reputation as the most trusted name in product protection. His leadership will put customers at the center, prioritize the execution of relevant innovation, and build brand equity. By combining customer centrality, innovation and brand building, McMillan will ensure Microban continues to deliver value for both industry partners and end-users. As president, McMillan will focus on building the Microban...

Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million…

In consideration for the immediate exercise in full of the Existing Warrants, the investors will receive, in a private placement, new unregistered warrants to purchase up to an aggregate of 14,720,920 of common stock shares (the “New Warrants”). The New Warrants will have an exercise price of $0.54 per share and, will be initially exercisable on the date that stockholder approval of the exercise of the New Warrants is obtained (the “Approval Date”) and will expire five (5) years following...

Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Requirement

Cosmos Health Inc. ("Cosmos Health" or the “Company”)(NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that on October 15, 2025, it received written notice (the ”Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the “Listing Rule”).In the Notice, Nasdaq stated that for the last 18 consecutive...

Zenos Wellness Summit Announces Transformative Keynote Lineup and Strategic…

Featured panel discussions include: Featured panel discussions include: Programming extends beyond keynotes to include morning yoga withLana Nazer, breathwork workshops by Arc ofSweden, a guided sunset walk through historic Diriyah by SANCTUM, and a signature Blue Lotus Ceremony by Bayan Abuzinada featuring adaptogenic elixirs and Yoga Nidra. Throughout the event, JEZALA Wellness will host a recovery lounge with infrared saunas, compression therapy, PEMF massage beds, and red light...

The 7iE Smart Matter WiFi Thermostat by Warmup

The First Underfloor Heating Controller with Matter Compatibility The First Underfloor Heating Controller with Matter Compatibility The 7iE Smart Matter WiFi Thermostat is Warmup's most advanced underfloor heating controller ever. Combining premium materials with market-leading automation innovation, the 7iE features Matter technology to ensure effortlessly integration with all major Smart home devices, including Apple Home, Google Home, and Amazon Alexa. Smarter Technology,...

Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value…

Event features full Phase 1 data and pivotal Phase 2 strategy for lasme-cel (UCART22) in r/r B-ALLNEW YORK, Oct.16, 2025(GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today hosts a R&D Day in New York City. The Company’s leadership team and key opinion leaders will present the full Phase 1 dataset and outline...

C-Path's Disease Modeling Coalition Begins Global Pediatric IBD Work from…

CP-DMC is being established with Quinten Health as the founding AI and disease modeling partner, working alongside both C-Path's Quantitative Medicine Program and Data Collaboration Center to integrate clinical trial and real-world data at scale for model development and application. CP-DMC is being established withQuinten Health as the founding AI and disease modeling partner, working alongside both C-Path's Quantitative Medicine Program and Data Collaboration Center to integrate clinical...

SOPHiA GENETICS Launches AI-Powered Digital Twins to Enhance Intelligent…

"Digital twin technology enables integrative visualization of multimodal oncologic data, revealing latent correlations across modalities. By simulating disease trajectories and therapeutic responses within a virtual environment, Digital Twins offer a framework for in silico experimentation, supporting anticipatory and individualized clinical decision-making," said Dr. Pierre Heudel, Medical Oncologist, Centre Léon Bérard. "Digital twin technology enables integrative visualization…

Sectra adds Smith+Nephew 3D templates to its orthopaedic solution--supporting…

"3D planning in orthopaedics is rapidly advancing and promises to play an important role in improving the efficiency and outcomes of trauma care. Sectra's integrated planning tools incorporating implant templates from leading brands like Smith+Nephew enhance our ability to prepare for complex procedures with precision and confidence." "3D planning in orthopaedics is rapidly advancing and promises to play an important role in improving the efficiency and outcomes of trauma…

Enterome receives FDA Fast Track designation in follicular lymphoma for lead…

Covers low tumor burden “watch-and-wait” setting, an unmet medical needRegistrational Phase 3 watch-and-wait to start in 2026EO2463 has broad potential to treat hemato-oncology indicationsParis, France – 16 OCTOBER, 2025 Enterome, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer,announces today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for follicular lymphoma in the low tumor burden...

The Board of Directors maintains its recommendation in supplementary statement…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONCOPENHAGEN, Denmark, October 16, 2025– Reference is made to Bavarian Nordic A/S' ("Bavarian Nordic" or the "Company") announcements of 26 August 2025 (no. 24/2025 and no. 25/2025) regarding the publication of the offer document, as amended by the supplements dated 29 September 2025…

Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney…

In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years 1 eGFR is key marker of kidney function; IgAN is progressive autoimmune kidney disease that leads to kidney failure in many patients 1-3 Fabhalta is first and only approved complement inhibitor for adults with IgAN and has potential to delay disease progression 4,5 ...

Roche presents major advances for its sequencing by expansion technology(1)…

Significant progress in bulk RNA sequencing, methylation mapping, multiomics integration, and spatial analyses unlocks research previously out of reach for traditional short read platforms.Leveraging Roche’s SBX technology, Broad Clinical Labs achieved the new GUINNESS WORLD RECORD™ for fastest DNA sequencing technique in under four hours, in collaboration with Roche Sequencing Solutions and Boston Children’s Hospital.Wellcome Sanger Institute joins a growing network of early...

Kuros Biosciences increases the annual guidance for 2025, The company reports…

Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences increases the annual guidance for 2025The company reports 77% year-over-year increase for the first nine months of 2025 Financial & Operational HighlightsTotal Medical Device sales rose by 77% to USD 101.1 million for the first nine months of 2025 (9M 2024: USD 57.2 million)Direct MagnetOs™ sales increased by 76% to USD 99.7 million for the first nine months of 2025 (9M 2024: USD 56...

Gastrointestinal Neuroendocrine Tumors Market Set to Surge by 2034 Amidst…

Gastrointestinal Neuroendocrine Tumors Market Summary Gastrointestinal Neuroendocrine Tumors Market Summary Discover the gastrointestinal neuroendocrine tumors new treatment @New Treatments for Gastrointestinal Neuroendocrine Tumors Key Factors Driving the Growth of the Gastrointestinal Neuroendocrine Tumors Market Rising GI-NET Incident Cases The total number of incident cases of GI-NETs in the US was nearly15,500 casesin 2024 and is projected to increase by 2034...

PENTAX Medical Announces Sale of C2 CryoBalloon™ Product Line to Merit Medical…

This strategic move allows PENTAX Medical to sharpen its focus on core endoscopic solutions while fostering deeper clinical partnerships. This strategic move allows PENTAX Medical to sharpen its focus on core endoscopic solutions while fostering deeper clinical partnerships. The C2 CryoBalloon™ has been part of PENTAX Medical's therapeutic portfolio since 2017, offering a minimally invasive option to treat patients suffering from Barrett's Esophagus and other gastrointestinal disorders...

Liposomal CBD Injection Technology (LPT-CBD) patent was allowed in Japan

This patent protects Innocan's LPT-CBD formulation designed for the sustained release of synthetic CBD into the bloodstream. The newly allowed patent is part of a broad international patent family currently under examination in multiple jurisdictions worldwide. It joins the company's granted patent in India, further strengthening Innocan global intellectual property portfolio and ensuring maximum protection and enforceability. With Japan being the world's third-largest pharmaceutical market…

OSE Immunotherapeutics Reports First Half 2025 Financial Results

OSE Immunotherapeutics Reports First Half 2025 Financial ResultsNANTES, France, October 15, 2025 – 7:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today reported its consolidated financial results for the first half of 2025.The half-year financial statements for 2025 were subject to a limited review by the Company’s statutory auditors and were approved by the Board of Directors on October 15, 2025. 2025 Half-Year Financial Results (IFRS)In million euros...

EssilorLuxottica acquires RetinAI, accelerating transformative AI and…

EssilorLuxottica acquires RetinAI, accelerating transformative AI and data-powered eye health solutionsParis, France (15 October 2025)– EssilorLuxottica announces the acquisition of Ikerian AG, a health technology company, operating under the RetinAI brand, specializing in AI and data management in eyecare. This move reinforces the Group’s med-tech journey, adding advanced software powered by machine learning and computer vision. These solutions streamline clinical, research and...

OXURION : Information on the Total Number of Voting Rights (Denominator)…

Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment[1]. Leuven, BELGIUM – 15 October, 2025 – 06:00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of…

IPSEN - Buy-back programme - Art 5 of MAR - Week 41 - 2025

Aggregated presentation by day and by marketStatement of transactions in own shares from October 06th to October 10th 2025 Name of the issueIdentity code of the issuer(Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1106/10/2025FR0010259150300...

Consortium consisting of Nordic Capital and Permira increases offer price and…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONCOPENHAGEN, Denmark, October 15, 2025– With reference to the announcement of 26 August 2025 (no. 24/2025) regarding the publication of the offer document (the "Offer Document " ) concerning the all-cash voluntary recommended public takeover offer to acquire all of the issued and outstanding...

Photocure and Intelligent Scopes Corporation partner on development of AI for…

In the current development phase, Photocure and ISC are collaborating to develop an AI software which can support the physician in real-time during blue light cystoscopy, improving early-stage bladder cancer detection, diagnosis, and resection completeness. The initial testing results were based on approximately 200 blue light procedures with more than 80,000 images. These results support the benefits of AI enabled blue light cystoscopy by detecting high risk cancerous lesions earlier in the…

Global Licensed Entertainment and Character Merchandise Market Set to Reach…

Get Free Sample Report What are the key factors driving the growth of the Licensed Entertainment and Character Merchandise Market? Source from Valuates Reports : https://reports.valuates.com/market-reports/QYRE-Auto-36H18456/global-licensed-entertainment-and-character-merchandise?utm_source=Prnewswire&utm_medium=Referral TRENDS INFLUENCING THE GROWTH OF THE LICENSED ENTERTAINMENT AND CHARACTER MERCHANDISE MARKET: Apparel plays a vital role in driving the...

Altri Comunicati